HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
EYE ON CHINA
Valsartan manufactured by Chinese company recalled over cancer risks
Made in China heart drug has been recalled across the country for presence of contaminant N-nitrosodimethylamine

In the latest medical safety scandal to hit China, the National Health Commission (NHC) has asked all medical institutions to stop using medicines containing the active ingredient valsartan produced by a domestic pharmaceutical company and to assist with related recalls.

The recall is due to an impurity involving the contaminant N-nitrosodimethylamine (NDMA), which was detected in the active pharmaceutical ingredients for valsartan, used to treat high blood pressure and heart failure. NDMA has been linked to cancer.

Medical institutions must not use the recalled drugs containing impurity-affected valsartan during diagnosis and treatment, said a statement by the NHC, which added that medical personnel should take efficient measures to ensure medical safety.

The statement also asked medical institutions to keep local medical authorities and regulators informed about their work on assisting with the recall and halting use of the recalled drugs.

The producer, Zhejiang Huahai Pharmaceutical Co. Ltd., halted shipments and launched voluntary recalls in domestic and foreign markets after it reported discovery of NDMA traces in its products for export to the drug regulator on 6 July 2018.

Source: Xinhua

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy